Ustekinumab
Top View
- INN Working Document 05.179 Update 2011
- STELARA® (Ustekinumab) Injection, for Subcutaneous Or Intravenous Use Subcutaneous Injection Initial U.S
- (INN) for Biological and Biotechnological Substances
- (Ustekinumab) Draft USPI STN: BL 125261/1 30 December, 2009
- EAACI IG Biologicals Task Force Paper on the Use of Biologic Agents in Allergic Disorders O
- Rxoutlook® 3Rd Quarter 2020
- Dendritic Cell-Mediated Th2 Immunity and Immune Disorders
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab
- Clinical Rx Forum Volume 5 Issue 2
- Secukinumab Emerges As a Rapidly Effective Therapy for Pityriasis Rubra Pilaris
- Tocilizumab Intravenous – (M0004)
- Phase II Multi-Centre, Double-Blind, Randomised Trial of Ustekinumab in Adolescents with New-Onset Type 1 Diabetes
- Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Medications That Are Immunosuppressive Or Immunomodulatory (This List Is Not All-Inclusive)
- Ustekinumab (Stelara) Is a Biologic Medication Medications
- A Pilot Study to Investigate Ustekinumab (STELARA®)